HPVNCT06674681
HPV Self-Collection Program
A study testing HPV Self-Collection in people with HPV, run by University of Utah at 1 site in United States.
Trial summary
The objective of the study is to develop, pilot, and analyze the effectiveness of HPV self-collection programs which will be used to follow up among women overdue for cervical cancer screening. Read more about this study
- Who is it for?
- Ages 25 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- HPV
- What is being tested?
- HPV Self-Collection
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,000 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Oct 2024to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women and individuals with a cervix.
- Aged 25-65 years during the study measurement period.
- Qualifying visit to the participating clinic.
- Overdue for cervical cancer screening.
- Those aged 24-64 who have not had cervical cytology (i.e., Pap test) performed within the last three and a half (3.5) years, or those aged 30-65 who have not had cervical HPV testing (i.e., primary HPV testing or contesting for HPV with Pap test) performed within the last five and a half (5.5) years.
Who cannot join
- Individuals without a cervix.
- Receiving hospice and/or palliative care during any part of the measurement period.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Utah Health Hospitals/Huntsman Cancer Institute Population Sciences
Salt Lake City, Utah, 84112
Stephen Gubler, stephen.gubler@hci.utah.edu
Deanna Kepka, PhD, MPH
About this study
The objective of the study is to develop, pilot, and analyze the effectiveness of HPV self-collection programs which will be used to follow up among women overdue for cervical cancer screening. The investigators will develop protocols for in-clinic and home-based HPV-self-collection programs and follow-up system for HPV-positive tests for community health centers and/or clinics. The program is meant to mail HPV-self-collection kits to women who are due and/or overdue for cervical cancer screening and the program is also meant to present women seen in clinic with a self-collection option for screening alongside a Pap test option. The research team will develop related informational resources on how to complete the test as well as information on screening options.
The study will neither experiment nor test the effectiveness of the self-collection process nor the assay of specimens for HPV and high-risk HPV strains. It is not a clinical investigation to assess the safety or effectiveness of a medical device. The study is implementation science and seeks to find optimal ways to implement this World Health Organization recommended screening option.
Read the detailed description
There are 2 parts of this project; (i) the implementation of a self-collection program at clinics/FQHCs (which is a quality improvement project) and (ii) the study/research portion (which is implementation science).
(i) The investigators will develop protocols and educational materials for an HPV-self-collection program that is conducted in a healthcare setting and/or in patients' homes. These materials will inform individuals about HPV, cervical cancer, and other HPV-related cancers. They will also instruct individuals how to use a self-collection kit. The research team will adapt existing clinical protocol implementation documents for self-collection programs (e.g., colorectal screening, HIV screening, etc.) from available resources and our previous work and collaborations. Implementation protocol and workflows will be created to meet the needs of the individual clinics, and designed for adaptability for other clinics and scalability to other additional and larger health systems.
Self-collection Implementation. Our clinic partners will implement new protocols for cervical cancer screening and follow-up for positive screening results, as developed in earlier stages of the study and as quality improvement. A new option for screening-self-collection-will be offered to eligible patients as an in-clinic option (e.g., collection in the exam room, restroom, mobile clinic) as well as an at-home option. These options will be offered alongside (or after) a recommendation for the patient to receive a Pap test (a.k.a., Pap smear). Patients who test positive for HPV will be followed up with by the clinics to schedule an appointment where they can discuss the next steps with their healthcare provider.
This research will not test the effectiveness of the tools or assay on detecting HPV. Clinics plan for participants to use the Copan swab to self-collect a sample and this will be a dry collection; the specimen will not need to be suspended in a medium or other substance. Clinics will send specimens to an external laboratory that has already validated the assay of self-collected specimens with the Copan swab. The lab's procedures are consistent with regulations for lab developed tests (LDTs). Considering recent FDA approval for a couple of devices used for self-collection in the healthcare setting, clinics may adopt these approved devices for the current study.
Medical records review will not currently be done for research purposes, only for recruitment and/or reviewing study eligibility.
(ii) The investigators will identify and assess the current patient-level barriers and facilitators to HPV self-collection and/or regular, in-clinic HPV screening. Staff at our partner clinics will review their records to identify eligible patients. They will share a de-identified data set (with the exception of the patients' residential zip code, county, date of clinic visits, and medical record number) with our research team. The research team will use the zip codes and county information to code each patient's rurality status and other area-based measures. After coding for rurality, the research team will remove and/or destroy zip codes from our data set(s). Each participant will receive a unique identifier and our team will only store medical record numbers and clinic visit dates in a separate file with a link to the unique identifiers. This study will store this file on a server with security protocols the University deems acceptable for PHI. The file will be accessed by the minimum study personnel necessary.
Additionally, the research team will survey patients who participate in the program at 2 points to assess patient-level barriers to HPV self-collection and understand confusion, ease, and fidelity of both the self-collection process and instructions. Patients will be recruited as described in the recruitment section of this application. Participants will be consented using a questionnaire cover letter, a consenting process for which the researchers request documentation of consent be waived. The research team will collect respondents' names in order to link their data across the 2 surveys. At a future point, this study will seek approval for a medical records review during which the investigators will link some information from their medical records to these survey data.
After its implementation, this research will (1) survey healthcare team members; (2) interview healthcare team members; (3) conduct a records review of patient-level data to assess screening choices, completion, results, and follow up; and (4) conduct analysis of the workflow to evaluate the effectiveness of the self-collection protocol. The research team will evaluate the HPV self-collection program at the clinic- and organization-levels for program effectiveness, reach, barriers and facilitators to adoption, implementation, and maintenance. Finally, the research team will conduct a data synthesis to capitalize on the richness of the mixed methods approach.
- Conditions
- HPV
- Being tested
- HPV Self-Collection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HPV Self-CollectionDiagnostic test
HPV self-collection program for in-clinic and mailed cervical cancer screening.
| Study group | Role | What they receive |
|---|---|---|
| HPV Self-Collection | Other | Patients at partnering clinics who are enrolled in the clinics' HPV self-collection program(s). The requirements for being enrolled in the program are based off of the American Cancer Society's recommendation for cervical cancer screening. Receives: Diagnostic Test: HPV Self-Collection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinic Level Implementation Rate
The proportion of people with a cervix who complete the test out of the number of people we were approached.
Measured: 1 year
Secondary outcomes (2)
At home utilization rate
The number of people who completed the test at home compared to the number of people who completed the test in clinic.
Measured: 1 year
Follow-up care rate
Among those with positive HVP test results, the number of people who complete recommended care.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2024
- Study start18 Oct 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HPVStudies of the same condition, open and under way.
- More trials run by University of UtahThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Deanna Kepka, PhD, MPH, Principal investigator, University of Utah
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06674681
- Sponsor's protocol ID
- HCI169477
- Other IDs
- 5R01CA279973-02
- Status last verified
- Feb 2026
- First submitted
- 29 Oct 2024
- Last updated
- 20 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HPV Self-Collection Program
- ClinicalTrials.gov ID
- NCT06674681
- Acronym / sponsor ID
- HCI169477
- Conditions
- HPV
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 18 Oct 2024 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 5 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to develop, pilot, and analyze the effectiveness of HPV self-collection programs which will be used to follow up among women overdue for cervical cancer screening. The investigators will develop protocols for in-clinic and home-based HPV-self-collection programs and follow-up system for HPV-positive tests for community health centers and/or clinics. The program is meant to mail HPV-self-collection kits to women who are due and/or overdue for cervical cancer screening and the program is also meant to present women seen in clinic with a self-collection option for screening alongside a Pap test option. The research team will develop related informational resources on how to complete the test as well as information on screening options.
The study will neither experiment nor test the effectiveness of the self-collection process nor the assay of specimens for HPV and high-risk HPV strains. It is not a clinical investigation to assess the safety or effectiveness of a medical device. The study is implementation science and seeks to find optimal ways to implement this World Health Organization recommended screening option.
Detailed description
There are 2 parts of this project; (i) the implementation of a self-collection program at clinics/FQHCs (which is a quality improvement project) and (ii) the study/research portion (which is implementation science).
(i) The investigators will develop protocols and educational materials for an HPV-self-collection program that is conducted in a healthcare setting and/or in patients' homes. These materials will inform individuals about HPV, cervical cancer, and other HPV-related cancers. They will also instruct individuals how to use a self-collection kit. The research team will adapt existing clinical protocol implementation documents for self-collection programs (e.g., colorectal screening, HIV screening, etc.) from available resources and our previous work and collaborations. Implementation protocol and workflows will be created to meet the needs of the individual clinics, and designed for adaptability for other clinics and scalability to other additional and larger health systems.
Self-collection Implementation. Our clinic partners will implement new protocols for cervical cancer screening and follow-up for positive screening results, as developed in earlier stages of the study and as quality improvement. A new option for screening-self-collection-will be offered to eligible patients as an in-clinic option (e.g., collection in the exam room, restroom, mobile clinic) as well as an at-home option. These options will be offered alongside (or after) a recommendation for the patient to receive a Pap test (a.k.a., Pap smear). Patients who test positive for HPV will be followed up with by the clinics to schedule an appointment where they can discuss the next steps with their healthcare provider.
This research will not test the effectiveness of the tools or assay on detecting HPV. Clinics plan for participants to use the Copan swab to self-collect a sample and this will be a dry collection; the specimen will not need to be suspended in a medium or other substance. Clinics will send specimens to an external laboratory that has already validated the assay of self-collected specimens with the Copan swab. The lab's procedures are consistent with regulations for lab developed tests (LDTs). Considering recent FDA approval for a couple of devices used for self-collection in the healthcare setting, clinics may adopt these approved devices for the current study.
Medical records review will not currently be done for research purposes, only for recruitment and/or reviewing study eligibility.
(ii) The investigators will identify and assess the current patient-level barriers and facilitators to HPV self-collection and/or regular, in-clinic HPV screening. Staff at our partner clinics will review their records to identify eligible patients. They will share a de-identified data set (with the exception of the patients' residential zip code, county, date of clinic visits, and medical record number) with our research team. The research team will use the zip codes and county information to code each patient's rurality status and other area-based measures. After coding for rurality, the research team will remove and/or destroy zip codes from our data set(s). Each participant will receive a unique identifier and our team will only store medical record numbers and clinic visit dates in a separate file with a link to the unique identifiers. This study will store this file on a server with security protocols the University deems acceptable for PHI. The file will be accessed by the minimum study personnel necessary.
Additionally, the research team will survey patients who participate in the program at 2 points to assess patient-level barriers to HPV self-collection and understand confusion, ease, and fidelity of both the self-collection process and instructions. Patients will be recruited as described in the recruitment section of this application. Participants will be consented using a questionnaire cover letter, a consenting process for which the researchers request documentation of consent be waived. The research team will collect respondents' names in order to link their data across the 2 surveys. At a future point, this study will seek approval for a medical records review during which the investigators will link some information from their medical records to these survey data.
After its implementation, this research will (1) survey healthcare team members; (2) interview healthcare team members; (3) conduct a records review of patient-level data to assess screening choices, completion, results, and follow up; and (4) conduct analysis of the workflow to evaluate the effectiveness of the self-collection protocol. The research team will evaluate the HPV self-collection program at the clinic- and organization-levels for program effectiveness, reach, barriers and facilitators to adoption, implementation, and maintenance. Finally, the research team will conduct a data synthesis to capitalize on the richness of the mixed methods approach.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| HPV Self-Collection | Other | Diagnostic Test: HPV Self-CollectionPatients at partnering clinics who are enrolled in the clinics' HPV self-collection program(s). The requirements for being enrolled in the program are based off of the American Cancer Society's recommendation for cervical cancer screening. |
Who may qualify
- Ages
- 25 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Women and individuals with a cervix.
- Aged 25-65 years during the study measurement period.
- Qualifying visit to the participating clinic.
- Overdue for cervical cancer screening.
- Those aged 24-64 who have not had cervical cytology (i.e., Pap test) performed within the last three and a half (3.5) years, or those aged 30-65 who have not had cervical HPV testing (i.e., primary HPV testing or contesting for HPV with Pap test) performed within the last five and a half (5.5) years.
Key exclusion criteria (2 listed)
- Individuals without a cervix.
- Receiving hospice and/or palliative care during any part of the measurement period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HPV Self-CollectionHPV self-collection program for in-clinic and mailed cervical cancer screening. | Diagnostic test | HPV Self-Collection |
Primary outcome
Clinic Level Implementation Rate
Time frame: 1 year
The proportion of people with a cervix who complete the test out of the number of people we were approached.
2 secondary outcomes
At home utilization rate
Time frame: 1 year
Follow-up care rate
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for HPV
Recruiting
Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda
HIV (Human Immunodeficiency Virus), HPV
Recruiting
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa
HIV (Human Immunodeficiency Virus), HPV
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
Recruiting
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive Women Living With HIV in C1001P-CS7 Zimbabwe
HIV (Human Immunodeficiency Virus), HPV
Active, not recruitingPhase 2/3
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Deanna Kepka, PhD, MPH principal investigator
University of Utah
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HPV Self-Collection in people with HPV, run by University of Utah at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Deanna Kepka (801-587-4565, Deanna.Kepka@hci.utah.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinic Level Implementation Rate (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Feb 2026.